Sequential (epi)genetic changes during liver cancer development and progression

Czauderna, Carolin; Poplawski, Andrzej; Castven, Darko; Franck, S; Heilmann‐Heimbach, Stefanie; Odenthal, Margarete; Amer, W; Andersen, Jesper; O’Rourke, Colm J.; Binder, Harald; Ridder, D. A.; Straub, Beate K.; Galle, PR; Ss, Thorgeirsson; Yn, Park; Marquardt, JU

doi:10.1055/s-0039-1695307

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, a small study conducted on 8 patients with HBV-HCC confirmed a progressive increase in hypermethylation through the transition from cirrhotic tissue to dysplastic nodules and HCC, with a peak of hypermethylation in eHCC samples. (42) In contrast to these studies and others, (10,18,42) our study incorporated the largest data set of genomewide DNA methylation and gene expression across different tissue types in the transition toward eHCC, thus allowing a more comprehensive approach in the identification of gatekeepers. However, one of the limitations of our study is the relatively small sample size of healthy tissue and dysplastic nodules.…”

Section: Discussionmentioning

confidence: 99%

DNA Methylation Profiling of Human Hepatocarcinogenesis

et al. 2021

View full text Add to dashboard Cite

BaCKgRoUND aND aIMS: Mutations in TERT (telomerase reverse transcriptase) promoter are established gatekeepers in early hepatocarcinogenesis, but little is known about other molecular alterations driving this process. Epigenetic deregulation is a critical event in early malignancies. Thus, we aimed to (1) analyze DNA methylation changes during the transition from preneoplastic lesions to early HCC (eHCC) and identify candidate epigenetic gatekeepers, and to (2) assess the prognostic potential of methylation changes in cirrhotic tissue. appRoaCH aND ReSUltS: Methylome profiling was performed using Illumina HumanMethylation450 (485,000 cytosine-phosphateguanine, 96% of known cytosinephosphateguanine islands), with data available for a total of 390 samples: 16 healthy liver, 139 cirrhotic tissue, 8 dysplastic nodules, and 227 HCC samples, including 40 eHCC below 2cm. A phylo-epigenetic tree derived from the Euclidean distances between differentially DNA-methylated sites (n = 421,997) revealed a gradient of methylation changes spanning healthy liver, cirrhotic tissue, dysplastic nodules, and HCC with closest proximity of dysplasia to HCC. Focusing on promoter regions, we identified epigenetic gatekeeper candidates with an increasing proportion of hypermethylated samples (beta value > 0.5) from cirrhotic tissue (<1%), to dysplastic nodules (≥25%), to eHCC (≥50%), and confirmed inverse correlation between DNA methylation and gene expression for TSPYL5 (testis-specific Y-encoded-like protein 5), KCNA3 (potassium voltage-gated channel, shaker-related subfamily, member 3), LDHB (lactate dehydrogenase B), and SPINT2 (serine peptidase inhibitor, Kunitz type 2) (all P < 0.001). Unsupervised clustering of genome-wide methylation profiles of cirrhotic tissue identified two clusters, M1 and M2, with 42% and 58% of patients, respectively, which correlates with survival (P < 0.05), independent of etiology.CoNClUSIoNS: Genome-wide DNA-methylation profiles accurately discriminate the different histological stages of human hepatocarcinogenesis. We report on epigenetic gatekeepers in the transition between dysplastic nodules and eHCC. DNA-methylation changes in cirrhotic tissue correlate with clinical outcomes. (Hepatology 2021;74:183-199).H CC, the most common form of primary liver cancer, typically occurs in patients with chronic liver disease, primarily cirrhosis. HBV and HCV virus infection, alcohol use disorder, and NAFLD are the major etiologies. (1) In the USA, the liver cancer death rate increased 43% between 2000 and 2016. (2) There is a limited understanding of the molecular events leading to malignant transformation in the context of cirrhosis. (3) Specifically, little is known about the molecular mechanisms that govern the transition from cirrhosis to dysplasia and early HCC (eHCC). TERT (telomerase reverse transcriptase) promoter mutations are the only bone fide early molecular events in hepatocarcinogenesis.

show abstract